Summary
The Phase 1b part of this study is conducted to assess the safety and tolerability of
E7386 in combination with pembrolizumab in participants with previously treated selected
solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in
combination with pembrolizumab.
The Phase 2 part of this study is conducted to assess the objective response rate (ORR)
of E7386 in combination with pembrolizumab (melanoma, colorectal cancer [CRC],
hepatocellular carcinoma [HCC]) or of E7386 in combination with pembrolizumab plus
lenvatinib (HCC) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.